Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

The median survival for metastatic melanoma is in the realm of 8–16 months and there are few therapies that offer significant improvement in overall survival. One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells....

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Oncol
Huvudupphovsmän: Woan, K.V., Lienlaf, M., Perez-Villaroel, P., Lee, C., Cheng, F., Knox, T., Woods, D.M., Barrios, K., Powers, J., Sahakian, E., Wang, H.W., Canales, J., Marante, D., Smalley, K.S.M., Bergman, J., Seto, E., Kozikowski, A., Pinilla-Ibarz, J., Sarnaik, A., Celis, E., Weber, J., Sotomayor, E.M., Villagra, A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2015
Ämnen:
Research Papers
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4523430/
https://ncbi.nlm.nih.gov/pubmed/25957812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.002
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk